查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2103856

子宮內避孕器市場：全球市場預測，2026-2032年

Intrauterine Devices Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，子宮內避孕器 (IUD) 市場將成長至 49.6 億美元，複合年成長率為 5.68%。

主要市場統計數據
基準年 2025 33.7億美元
預計年份：2026年 35億美元
預測年份 2032 49.6億美元
複合年成長率 (%) 5.68%

避孕器（IUD）執行摘要

避孕器（IUD）是最有效的長效可逆避孕方法之一，可提供數年的避孕保護，且對使用者來說幾乎沒有不便。此類避孕器包括不含荷爾蒙的銅子宮內避孕器和釋放levonorgestrel的荷爾蒙子宮內避孕器。後者在臨床上也用於治療某些患者的月經過多和其他婦科疾病。由於子宮內避孕器具有高效、取出後可快速恢復以及適用於各個生育階段的人群等優點，世界各地的公共衛生組織都將其視為一種核心避孕選擇。

避孕器領域的變革性變化

避孕器（IUD）的格局正在重塑，其理念正從「統一的避孕方法」轉向「以病人為中心的避孕諮詢」。醫療保健系統日益強調知情選擇、共同決策和取出途徑，這反映了全球指南的指南，即避孕項目應尊重個人自主權，避免強制放置。這凸顯了就益處、副作用、放置過程中的不適、脫落風險、穿孔風險、出血模式變化以及及時取出等問題進行平衡溝通的重要性。

人工智慧（AI）對子宮內避孕器取得和照護的累積影響

人工智慧 (AI) 正透過支援臨床工作流程、促進病患參與、監測藥物安全性和最佳化供應計劃，逐步影響避孕器(IUD) 生態系統。在臨床實踐中，AI 工具可以幫助系統化風險因素篩檢、規範諮詢指南、協助安排就診優先級，並識別植入後追蹤的必要性。雖然這些應用不能取代臨床醫生的判斷，但它們可以減少資訊疏漏、提高記錄一致性，並支持更安全的照護路徑。

亞太地區、北美地區、拉丁美洲地區、歐洲地區以及中東和非洲地區的關鍵區域洞察

亞太地區子宮內避孕器（IUD）的使用情況呈現出高度多樣化的格局，其普及程度受各國計劃生育歷史、都市區醫療保健差異、醫療服務提供者數量以及公共部門採購等因素的影響。擁有完善公共衛生網路和大規模孕產婦保健體系的國家能夠提供更多產後和流產後IUD服務，而都市區私立診所則為尋求長效可逆避孕方式的消費者提供含激素和含銅IUD。在亞太地區的某些地區，關於不孕症、疼痛以及IUD是否適用於未生育女性的誤解仍然存在，因此高品質的諮商服務至關重要。

針對東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約的關鍵群體特定見解

在東南亞國協，避孕器（IUD）的使用模式因公共計劃生育基礎設施、都市區私立診所、宗教和文化規範以及醫護人員培訓水平的差異而有所不同。隨著各國加強全民健康覆蓋（UHC）和孕產婦保健計劃，子宮內避孕器的可及性越來越依賴主要城市以外地區的可靠供應、高品質的諮詢和服務。海灣合作理事會（GCC）地區擁有先進的醫院基礎設施，女性在教育和勞動力市場中的參與度不斷提高，人們越來越傾向於在私立和專業醫療機構中使用隱蔽、長效的避孕方法，但文化敏感的諮詢仍然是提高接受度的關鍵。

對主要避孕器（IUD）市場進行國別分析。

在美國，避孕保險覆蓋範圍、生殖保健服務取得、醫療專業人員數量以及各省服務提供方面的差異仍然產生重大影響。在加拿大，完善的臨床指南和公眾對避孕經濟負擔日益成長的認知是積極因素，但服務獲取情況因省份、農村地區和原住民社區而異。墨西哥和巴西擁有完善的公共衛生體系，能夠支持避孕服務，但地區差異、診所容量和諮詢品質影響著子宮內避孕器（避孕器）的穩定供應。

為避孕器產業領導者提供的實用建議

產業領導者應優先考慮以實證醫學為基礎、以權利為本的准入策略，以增強病患信任和提升臨床品質。這包括投資於醫護人員的培訓，內容涵蓋插入技術、疼痛管理方案、合格評估、出血變化處理、出院須知、感染預防以及及時取出等。訓練範圍應不僅限於婦產科醫生，還應擴展到基層醫療、流產後護理以及社區生殖健康計畫（如法規允許）。

調查方法

本執行摘要採用系統化的二手資料研究途徑編寫，重點關注檢驗的公共衛生、臨床、監管和政策資訊來源。資訊來源包括權威衛生機構的指導意見、同行評審的醫學文獻、國家生殖健康指南、監管文件、避孕安全性參考文獻以及公開的醫療保健系統資訊。本檢驗著重闡述了關於子宮內避孕器（IUD）的有效性、安全性、取得障礙、服務提供模式和區域政策趨勢的已驗證證據。

結論

避孕器（IUD）領域正在更廣泛的生殖健康背景下發展，這一背景以患者自主權、臨床品質、經濟性和公平獲取為特徵。雖然含銅和含激素子宮內避孕器仍然是重要的長效可逆避孕方法，但其廣泛應用並非僅取決於避孕器的性能。值得信賴的諮詢、熟練的放置和取出服務、政策支援以及可靠的供應鏈，如今才是持續推廣的關鍵。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：子宮內避孕器市場：依器械類型分類

  • 銅
  • 荷爾蒙

第8章：子宮內避孕器市場：依使用時間分類

  • 5年或以上
  • 3-5年
  • 不到3年

第9章：子宮內避孕器市場：依分銷管道分類

  • 線上
  • 離線

第10章：子宮內避孕器市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 專科診所

第11章：子宮內避孕器市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章：子宮內避孕器市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章：子宮內避孕器市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Actavis Generics by Teva Pharmaceutical Industries Ltd.
  • Agile Therapeutics, Inc.
  • Allergan Plc by Abbvie Inc
  • Ava AG
  • Bayer AG
  • Cardinal Health, Inc.
  • Contrel Europe nv
  • CooperSurgical Inc.
  • Egemen International
  • ERENLER MEDIKAL SAN. TIC. LTD. STI.
  • Eurogine SL
  • Fuji Latex Co., Ltd.
  • HLL Lifecare Limited
  • HRA Pharma, SAS
  • Melbea AG
  • Merck & Co., Inc.
  • Meril Life Sciences Pvt. Ltd.
  • Mona Lisa NV
  • Mylan NV by Viatris Inc.
  • Novartis AG
  • Ocon Medical Ltd
  • Pregna International Limited
  • Prosan International BV
  • Searchlight Pharma Inc.
  • SMB Corporation of India
Product Code: MRR-8E22B61932AA

The Intrauterine Devices Market is projected to grow by USD 4.96 billion at a CAGR of 5.68% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.37 billion
Estimated Year [2026] USD 3.50 billion
Forecast Year [2032] USD 4.96 billion
CAGR (%) 5.68%

Intrauterine Devices Executive Summary

Intrauterine devices (IUDs) are among the most effective forms of long-acting reversible contraception, offering multi-year pregnancy prevention with minimal user maintenance. The category includes copper IUDs, which provide hormone-free contraception, and levonorgestrel-releasing hormonal IUDs, which are also used clinically for heavy menstrual bleeding and other gynecologic indications in selected patients. Global public health bodies recognize IUDs as a core component of contraceptive choice because they combine high contraceptive effectiveness, rapid reversibility after removal, and suitability for many individuals across reproductive life stages.

Demand for intrauterine devices is shaped by reproductive autonomy, access to trained healthcare providers, insurance coverage or public procurement, patient education, and post-partum and post-abortion family planning services. The industry is also influenced by quality assurance requirements, device safety surveillance, regulatory labeling, sterile manufacturing standards, and procurement policies in public health systems. As governments and healthcare organizations prioritize prevention, maternal health, and rights-based family planning, IUD adoption increasingly depends on trust, counseling quality, affordability, and equitable access rather than product efficacy alone.

Transformative Shifts in the Intrauterine Devices Landscape

The intrauterine devices landscape is being reshaped by a shift from one-size-fits-all contraception toward patient-centered contraceptive counseling. Healthcare systems are increasingly emphasizing informed choice, shared decision-making, and removal access, reflecting global guidance that contraceptive programs should respect autonomy and avoid coercive uptake targets. This has elevated the importance of balanced communication on benefits, side effects, insertion discomfort, expulsion risk, perforation risk, bleeding pattern changes, and timely removal.

Clinical practice is also moving toward broader access points. Post-partum IUD placement, post-abortion insertion, and integration of contraception into primary care and community health services are expanding where provider training and supply continuity are available. At the same time, misinformation about fertility, pelvic inflammatory disease, pain, and hormonal exposure continues to influence patient decisions, making evidence-based counseling a strategic differentiator.

Product and service models are evolving around comfort, convenience, and continuity of care. Smaller-frame devices, improved inserter design, ultrasound-supported placement when clinically appropriate, digital appointment reminders, and stronger adverse-event reporting pathways are gaining relevance. Across both high-income and emerging health systems, the most important transformation is the convergence of medical quality, user experience, and reproductive rights into a single access agenda.

Cumulative Impact of Artificial Intelligence on IUD Access and Care

Artificial intelligence is beginning to affect the intrauterine devices ecosystem through clinical workflow support, patient engagement, pharmacovigilance, and supply planning. In clinical settings, AI-enabled tools can help organize risk-factor screening, standardize counseling prompts, support appointment triage, and flag follow-up needs after insertion. These applications do not replace clinician judgment but can reduce missed information, improve documentation consistency, and support safer care pathways.

AI also has practical value in patient education. Natural-language tools and multilingual digital assistants can provide evidence-based answers on IUD types, expected bleeding changes, warning signs, fertility return after removal, and when to seek care. For health systems, AI can strengthen outreach for post-partum and interval contraception visits, identify populations facing access barriers, and improve scheduling efficiency while maintaining privacy safeguards.

On the operational side, AI can assist manufacturers and public procurement bodies by improving demand planning, monitoring distribution disruptions, and analyzing real-world safety signals from structured and unstructured data. The cumulative impact will depend on transparent algorithms, validated clinical content, cybersecurity, bias mitigation, and compliance with medical device and health data regulations. The highest-value AI use cases are those that improve informed consent, reduce administrative burden, and enhance continuity of care without undermining patient autonomy.

Key Regional Insights Across Asia-Pacific, North America, Latin America, Europe, the Middle East, and Africa

Asia-Pacific represents a highly diverse intrauterine devices environment, with uptake shaped by national family planning histories, urban-rural healthcare disparities, provider availability, and public-sector procurement. Countries with extensive public health networks and high-volume maternal care systems are expanding opportunities for post-partum and post-abortion IUD services, while private-sector urban clinics support access to hormonal and copper options for consumers seeking long-acting reversible contraception. In parts of the region, persistent myths about infertility, pain, and suitability for nulliparous users continue to make counseling quality essential.

North America is characterized by established clinical guidelines, high awareness of long-acting reversible contraception, and a strong role for insurance coverage, outpatient gynecology, and primary care services. The United States and Canada continue to face policy attention around contraceptive coverage, reproductive health access, and equity, making affordability and availability central to IUD utilization. Latin America has long-standing public health engagement with contraception, but access varies by country, income level, and service setting; public procurement, adolescent-friendly care, and provider training remain important for equitable IUD availability.

Europe benefits from mature regulatory systems, strong clinical governance, and widespread integration of contraception into public or mixed healthcare models. However, reimbursement policies, prescribing norms, and cultural attitudes vary across Western, Northern, Southern, and Eastern Europe, affecting the balance between hormonal IUDs and copper IUDs. In the Middle East, IUD adoption is influenced by maternal health priorities, private healthcare growth, and cultural considerations around family planning counseling. Africa presents significant unmet need for modern contraception in many settings, and IUD access is closely tied to trained provider density, commodity security, donor-supported programs, and integration with maternal and child health services.

Key Group Insights Across ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN countries show varied intrauterine devices adoption patterns driven by public family planning infrastructure, urban private clinics, religious and cultural norms, and differing levels of provider training. As countries strengthen universal health coverage and maternal health programs, IUD availability increasingly depends on ensuring reliable supplies, quality counseling, and services beyond major cities. The GCC region is shaped by advanced hospital infrastructure, rising participation of women in education and the workforce, and a growing preference for discreet, long-acting contraceptive options in private and specialist care settings, while culturally sensitive counseling remains central to acceptance.

The European Union provides a regulated environment with strong emphasis on safety, clinical evidence, and patient rights. Access varies by national reimbursement policy, age-based subsidy structures, and the extent to which contraception is embedded in primary care or specialist gynecology. BRICS countries represent a major cross-section of public health systems, domestic manufacturing capacity, and large reproductive-age populations. In these countries, IUD strategies are influenced by government procurement, urban-rural service gaps, local clinical guidelines, and efforts to expand modern contraceptive choice.

The G7 countries generally demonstrate advanced regulatory oversight, established professional guidelines, and greater availability of both hormonal and copper IUD options, yet disparities persist for adolescents, low-income populations, rural residents, migrants, and uninsured or underinsured groups. NATO member countries overlap significantly with high-income European and North American settings, where healthcare system resilience, supply chain security, and standardized clinical training support IUD access. Across all these groups, the strongest opportunities are linked to rights-based counseling, affordability, resilient supply chains, and improved provider competence.

Key Country Insights for Major Intrauterine Devices Markets

The United States remains highly influenced by contraceptive coverage policy, reproductive healthcare access, clinician availability, and state-level differences in service delivery. Canada benefits from strong clinical guidance and increasing public attention to contraceptive affordability, though access can differ across provinces, rural areas, and Indigenous communities. Mexico and Brazil have extensive public health systems that support contraceptive access, but regional inequality, clinic capacity, and counseling quality affect consistent availability of intrauterine devices.

In Europe, the United Kingdom has a well-developed sexual and reproductive health service framework, although service pressures can affect appointment availability. Germany, France, Italy, and Spain show mature healthcare systems with differing reimbursement pathways, clinical traditions, and consumer preferences between hormonal and copper IUDs. Russia has a large healthcare infrastructure and established gynecologic service base, with adoption shaped by clinical practice patterns, product availability, and patient perceptions of hormonal and non-hormonal contraception.

China has a long history of IUD use through population and family planning systems, and current demand is evolving as reproductive policy, fertility preferences, and patient choice change. India presents significant potential for expanded access through public-sector reproductive health programs, but uptake depends on provider training, awareness, and confidence in reversible methods. Japan has comparatively lower reliance on IUDs than several Western countries, reflecting prescribing norms, regulatory history, and patient preference patterns, while Australia benefits from evidence-based clinical guidelines, primary care integration, and public health attention to long-acting reversible contraception. South Korea's advanced healthcare infrastructure and high digital health adoption support informed access, though cultural preferences and provider counseling continue to shape IUD utilization.

Actionable Recommendations for Intrauterine Devices Industry Leaders

Industry leaders should prioritize evidence-based, rights-centered access strategies that strengthen patient trust and clinical quality. This includes investing in provider education on insertion technique, pain management options, eligibility assessment, management of bleeding changes, expulsion recognition, infection prevention, and timely removals. Training should extend beyond specialist gynecology to primary care, post-partum care, post-abortion services, and community-linked reproductive health programs where regulations allow.

Manufacturers and healthcare stakeholders should improve product availability through resilient supply chains, clear labeling, sterile quality systems, and alignment with national procurement requirements. Patient-facing education should be multilingual, culturally appropriate, and transparent about both benefits and potential side effects. Digital tools can support reminders, follow-up guidance, and adverse-event reporting, but they must protect personal health data and avoid replacing clinician-led informed consent.

Strategic growth should focus on expanding contraceptive choice rather than promoting any single method. Leaders should collaborate with public health agencies, professional societies, and community organizations to reduce misinformation, improve affordability, and address underserved populations. Continuous real-world evidence generation, post-market surveillance, and user-experience research will be essential for sustaining confidence in intrauterine devices.

Research Methodology

This executive summary is developed through a structured secondary research approach focused on verified public health, clinical, regulatory, and policy sources. Inputs include guidance from recognized health authorities, peer-reviewed medical literature, national reproductive health guidelines, regulatory documentation, contraceptive safety references, and publicly available health system information. The analysis emphasizes validated evidence on IUD effectiveness, safety considerations, access barriers, service delivery models, and regional policy dynamics.

The methodology excludes speculative market sizing, revenue estimation, market share calculations, and forecasting. Findings are synthesized to identify qualitative trends, regional patterns, group-level dynamics, and country-specific access factors. Data interpretation prioritizes clinical credibility, reproducibility, and relevance to decision-makers across manufacturing, healthcare delivery, procurement, policy, and reproductive health services.

Where regional or country comparisons are made, they are framed around documented differences in healthcare infrastructure, public family planning programs, reimbursement policy, regulatory maturity, provider training, and patient access. The resulting insights are intended to support strategic planning while maintaining a rights-based and evidence-driven view of intrauterine devices.

Conclusion

The intrauterine devices sector is advancing within a broader reproductive health environment defined by patient autonomy, clinical quality, affordability, and equitable access. Copper and hormonal IUDs remain essential long-acting reversible contraceptive options, but their adoption depends on much more than device performance. Trustworthy counseling, skilled insertion and removal services, policy support, and reliable supply chains are now central to sustainable uptake.

Regional and country-level differences show that successful strategies must be localized. High-income health systems require stronger equity, coverage, and service capacity, while emerging and underserved settings need investments in training, commodity security, and community-informed education. Artificial intelligence can improve education, workflow, and safety monitoring when implemented responsibly, but it must reinforce-not replace-patient-centered care.

Industry leaders that align innovation with evidence, rights-based counseling, and health system realities will be best positioned to support broader access to intrauterine devices and strengthen confidence in modern contraceptive care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Intrauterine Devices Market, by Device Type

  • 7.1. Introduction
  • 7.2. Copper
  • 7.3. Hormonal

8. Intrauterine Devices Market, by Usage Duration

  • 8.1. Introduction
  • 8.2. Over Five Years
  • 8.3. Three To Five Years
  • 8.4. Under Three Years

9. Intrauterine Devices Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Online
  • 9.3. Offline

10. Intrauterine Devices Market, by End User

  • 10.1. Introduction
  • 10.2. Ambulatory Surgical Centers
  • 10.3. Hospitals
  • 10.4. Specialty Clinics

11. Intrauterine Devices Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Intrauterine Devices Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Intrauterine Devices Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2025
  • 14.2. FPNV Positioning Matrix, 2025
  • 14.3. Market Concentration Analysis, 2025
    • 14.3.1. Concentration Ratio (CR)
    • 14.3.2. Herfindahl Hirschman Index (HHI)
  • 14.4. Recent Developments & Impact Analysis, 2025
  • 14.5. Product Portfolio Analysis, 2025
  • 14.6. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Actavis Generics by Teva Pharmaceutical Industries Ltd.
  • 15.2. Agile Therapeutics, Inc.
  • 15.3. Allergan Plc by Abbvie Inc
  • 15.4. Ava AG
  • 15.5. Bayer AG
  • 15.6. Cardinal Health, Inc.
  • 15.7. Contrel Europe nv
  • 15.8. CooperSurgical Inc.
  • 15.9. Egemen International
  • 15.10. ERENLER MEDIKAL SAN. TIC. LTD. STI.
  • 15.11. Eurogine S.L.
  • 15.12. Fuji Latex Co., Ltd.
  • 15.13. HLL Lifecare Limited
  • 15.14. HRA Pharma, SAS
  • 15.15. Melbea AG
  • 15.16. Merck & Co., Inc.
  • 15.17. Meril Life Sciences Pvt. Ltd.
  • 15.18. Mona Lisa N.V.
  • 15.19. Mylan NV by Viatris Inc.
  • 15.20. Novartis AG
  • 15.21. Ocon Medical Ltd
  • 15.22. Pregna International Limited
  • 15.23. Prosan International BV
  • 15.24. Searchlight Pharma Inc.
  • 15.25. SMB Corporation of India

LIST OF FIGURES

  • FIGURE 1. GLOBAL INTRAUTERINE DEVICES MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL INTRAUTERINE DEVICES MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL INTRAUTERINE DEVICES MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL INTRAUTERINE DEVICES MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL INTRAUTERINE DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 21. GLOBAL INTRAUTERINE DEVICES MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL INTRAUTERINE DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COPPER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COPPER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COPPER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HORMONAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HORMONAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HORMONAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL OVER FIVE YEARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL OVER FIVE YEARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL OVER FIVE YEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL THREE TO FIVE YEARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL THREE TO FIVE YEARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL THREE TO FIVE YEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL UNDER THREE YEARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL UNDER THREE YEARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL UNDER THREE YEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC INTRAUTERINE DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 43. NORTH AMERICA INTRAUTERINE DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. NORTH AMERICA INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 45. NORTH AMERICA INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 46. NORTH AMERICA INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 47. NORTH AMERICA INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 48. LATIN AMERICA INTRAUTERINE DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. LATIN AMERICA INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 50. LATIN AMERICA INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 51. LATIN AMERICA INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 52. LATIN AMERICA INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 53. EUROPE INTRAUTERINE DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. EUROPE INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. EUROPE INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 56. EUROPE INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 57. EUROPE INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. MIDDLE EAST INTRAUTERINE DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. MIDDLE EAST INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. MIDDLE EAST INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 61. MIDDLE EAST INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 62. MIDDLE EAST INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. AFRICA INTRAUTERINE DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. AFRICA INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. AFRICA INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 66. AFRICA INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. AFRICA INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. ASEAN INTRAUTERINE DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. ASEAN INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. ASEAN INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 72. ASEAN INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. ASEAN INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. GCC INTRAUTERINE DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GCC INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. GCC INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 77. GCC INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 78. GCC INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPEAN UNION INTRAUTERINE DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPEAN UNION INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPEAN UNION INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPEAN UNION INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPEAN UNION INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. BRICS INTRAUTERINE DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. BRICS INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. BRICS INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 87. BRICS INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. BRICS INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. G7 INTRAUTERINE DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. G7 INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. G7 INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 92. G7 INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. G7 INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. NATO INTRAUTERINE DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. NATO INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. NATO INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 97. NATO INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. NATO INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. UNITED STATES INTRAUTERINE DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 101. UNITED STATES INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. UNITED STATES INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 103. UNITED STATES INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. UNITED STATES INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. CANADA INTRAUTERINE DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 106. CANADA INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. CANADA INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 108. CANADA INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. CANADA INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. MEXICO INTRAUTERINE DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 111. MEXICO INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. MEXICO INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 113. MEXICO INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. MEXICO INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. BRAZIL INTRAUTERINE DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 116. BRAZIL INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. BRAZIL INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 118. BRAZIL INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. BRAZIL INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. UNITED KINGDOM INTRAUTERINE DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 121. UNITED KINGDOM INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. UNITED KINGDOM INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 123. UNITED KINGDOM INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. UNITED KINGDOM INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. GERMANY INTRAUTERINE DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 126. GERMANY INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. GERMANY INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 128. GERMANY INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. GERMANY INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. FRANCE INTRAUTERINE DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 131. FRANCE INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. FRANCE INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 133. FRANCE INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. FRANCE INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. RUSSIA INTRAUTERINE DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 136. RUSSIA INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. RUSSIA INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 138. RUSSIA INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. RUSSIA INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. ITALY INTRAUTERINE DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 141. ITALY INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. ITALY INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 143. ITALY INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. ITALY INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. SPAIN INTRAUTERINE DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. SPAIN INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. SPAIN INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 148. SPAIN INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. SPAIN INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA INTRAUTERINE DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. CHINA INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. INDIA INTRAUTERINE DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 156. INDIA INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. INDIA INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 158. INDIA INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. INDIA INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. JAPAN INTRAUTERINE DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. JAPAN INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. JAPAN INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 163. JAPAN INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. JAPAN INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. AUSTRALIA INTRAUTERINE DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 166. AUSTRALIA INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. AUSTRALIA INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 168. AUSTRALIA INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. AUSTRALIA INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. SOUTH KOREA INTRAUTERINE DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 171. SOUTH KOREA INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. SOUTH KOREA INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 173. SOUTH KOREA INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. SOUTH KOREA INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL INTRAUTERINE DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 176. GLOBAL INTRAUTERINE DEVICES MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025